We are proud that Humana is offering its members coverage for the only gene expression test for breast cancer recurrence which has been cleared by the FDA. .. Agendia establishes agreement with Humana for coverage of MammaPrint breast malignancy recurrence test Agendia, a global leader in molecular malignancy diagnostics, announced today that it has generated a contract with leading insurance carrier Humana to reimburse for the company’s MammaPrint test. Agendia’s agreement with Humana expands the coverage for MammaPrint by more than 17 million lives. In 2009 November, Palmetto GBA, California’s Component B Medicare administrator, set up coding recommendations for MammaPrint, allowing healthcare providers from across the United States to submit promises for the check.For each model, we assessed the interaction between study study and treatment time, which was defined as a continuous variable to test if the proportional-hazards assumption was violated. Interactions between prepared covariates and antiplatelet assignment were evaluated with the use of Cox versions to determine whether the treatment effect differed in specific subgroups. All analyses had been predicated on the intention-to-treat principle. The trial was monitored by an unbiased data and safety monitoring committee selected by the scholarly study sponsor. At the recommendation of the basic safety and data monitoring committee, the antiplatelet element of the trial was stopped by the sponsor 10 months prior to the planned end date, after completion of the next planned interim analysis, due to futility with respect to the primary final result coupled with evidence of harm.